久久久受www免费人成,夜夜高潮夜夜爽夜夜爱爱,午夜美女裸体福利视频

FOLFIRI Regimen

NMR下載 COA and HPLC MSDS下載
names：
FOLFIRI Regimen
CAS號：
1000669-05-5
MDL Number：
MF(分子式)： C57H64FN13O15 MW(分子量)： 1190.21
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

貨品編碼	規(guī)格	純度	價格 (￥)	現(xiàn)價(￥)	特價(￥)	庫存描述	數(shù)量	總計 (￥)

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產(chǎn)品

*產(chǎn)品名稱：

CAS號：

產(chǎn)品編號：

需求描述：

請準確填寫您的聯(lián)系方式，以便為您提供最好的服務。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗證碼：

詢價

中文別名	(4-(((2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl)methyl)amino)benzoyl)-L-glutamic acid compound with (S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4'6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylate and 5-fluoropyrimidine-2,4(1H,3H)-dione (111)
英文別名	FOLFIRI Regimen; FOLFIRI; 5-Fluorouracil mixture with Folinic acid and Irinotecan;
CAS號	1000669-05-5
Inchi	1S/C33H38N4O6.C20H23N7O7.C4H3FN2O2/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2;21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30;5-2-1-6-4(9)7-3(2)8/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3;1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32);1H,(H2,6,7,8,9)/t33-;12?,13-;/m00./s1
InchiKey	JYEFSHLLTQIXIO-SMNQTINBSA-N
分子式 Formula	C57H64FN13O15
分子量 Molecular Weight	1190.21
溶解度Solubility
性狀	Solid powder
儲藏條件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

產(chǎn)品說明	FOLFIRI Regimen(CAS:1000669-05-5):僅限應用于工業(yè)或者科學研究過程中非醫(yī)療目的，不應用于人類或動物的臨床診斷以及治過程療，該產(chǎn)品非藥用，非食用。
Introduction	FOLFIRI Regimen is a chemotherapy regimen consisting of leucovorin calcium (calcium folinate), 5-fluorouracil, and irinotecan used in the treatment of advanced-stage and metastatic colorectal cancer.
Application1
Application2
Application3

警示圖
危險性	Warning
危險性警示
安全聲明
安全防護
備注

[1]Sánchez-Gundín J, Fernández-Carballido AM, Martínez-Valdivieso L, Barreda-Hernández D, Torres-Suárez AI. New Trends in the Therapeutic Approach to Metastatic Colorectal Cancer. Int J Med Sci. 2018 Apr 3;15(7):659-665. doi: 10.7150/ijms.24453. eCollection 2018. Review. PubMed PMID: 29910669; PubMed Central PMCID: PMC6001415.

[2]Johnson WR, Theeler BJ, Van Echo D, Young P, Kwok M. Treatment of Leptomeningeal Carcinomatosis in a Patient with Metastatic Pancreatic Cancer: A Case Report and Review of the Literature. Case Rep Oncol. 2018 May 17;11(2):281-288. doi: 10.1159/000489085. eCollection 2018 May-Aug. PubMed PMID: 29867436; PubMed Central PMCID: PMC5981627.

[3] Kim ST, Kim HK, Lee J, Park SH, Lim HY, Park YS, Kang WK, Park JO. The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer. J Cancer. 2018 Apr 19;9(10):1791-1796. doi: 10.7150/jca.25132. eCollection 2018. PubMed PMID: 29805705; PubMed Central PMCID: PMC5968767.

[4] Haghighi S, Noorali S, Mohammad Alizadeh AH. Cronkhite-Canada Syndrome Associated with Metastatic Colon Cancer. Case Rep Gastroenterol. 2018 Apr 13;12(1):109-115. doi: 10.1159/000479220. eCollection 2018 Jan-Apr. PubMed PMID: 29805353; PubMed Central PMCID: PMC5968282.

[5] Das S, Ciombor KK, Haraldsdottir S, Goldberg RM. Promising New Agents for Colorectal Cancer. Curr Treat Options Oncol. 2018 May 11;19(6):29. doi: 10.1007/s11864-018-0543-z. Review. PubMed PMID: 29752549.

6: Tokoro T, Nakamura K, Hirose A, Nakanuma S, Okamoto K, Kinoshita J, Makino I, Hayashi H, Oyama K, Miyashita T, Tajima H, Takamura H, Ninomiya I, Fushida S, Ohta T. [A Case of Colon Cancer with Brain, Liver and Lung Metastasis Successfully Treated with Bevacizumab plus Xelox Therapy]. Gan To Kagaku Ryoho. 2018 Mar;45(3):521-523. Japanese. PubMed PMID: 29650925.7: Pastorino A, Di Bartolomeo M, Maiello E, Iaffaioli V, Ciuffreda L, Fasola G, Di Costanzo F, Frassineti GL, Marchetti P, Antoniotti C, Leone F, Zaniboni A, Aprile G, Zilocchi C, Sobrero A, Bordonaro R. Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study. Clin Colorectal Cancer. 2018 Mar 8. pii: S1533-0028(18)30050-1. doi: 10.1016/j.clcc.2018.03.002. [Epub ahead of print] PubMed PMID: 29605592.8: Xu RH, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS, Kim TW. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2018 May;19(5):660-671. doi: 10.1016/S1470-2045(18)30140-2. Epub 2018 Mar 16. PubMed PMID: 29555258.9: Oki E, Kato T, Bando H, Yoshino T, Muro K, Taniguchi H, Kagawa Y, Yamazaki K, Yamaguchi T, Tsuji A, Iwamoto S, Nakayama G, Emi Y, Touyama T, Nakamura M, Kotaka M, Sakisaka H, Yamanaka T, Kanazawa A. A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study. Clin Colorectal Cancer. 2018 Jun;17(2):147-155. doi: 10.1016/j.clcc.2018.01.011. Epub 2018 Feb 9. PubMed PMID: 29530335.10: Munemoto Y, Kanda M, Oba K, Kim HM, Takemoto H, Denda T, Nagata N, Takano N, Fukunaga M, Kataoka M, Tokunaga Y, Sakamoto J, Mishima H. A phase II trial to evaluate the efficacy of panitumumab combined with fluorouracil-based chemotherapy for metastatic colorectal cancer: the PF trial. Cancer Chemother Pharmacol. 2018 May;81(5):829-838. doi: 10.1007/s00280-018-3556-1. Epub 2018 Mar 5. PubMed PMID: 29508026.1

對不起，暫無產(chǎn)品評價！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開